AbbVie (ABBV): financials, SEC filings and peers
AbbVie (ABBV) is a biotechnology company in the Health Care sector of the S&P 500, headquartered in North Chicago, Illinois.
It was founded in 2013 and joined the S&P 500 on December 31, 2012.
Its fiscal year ends in December, and its shares trade on the NYSE.
In its SEC filings it is classified as “Pharmaceutical Preparations”.
AbbVie at a glance
- Revenue (12 months)
- $66.0B
- Revenue growth
- +10.7%
- Operating margin
- 32.2%
- Net income (12 months)
- $10.3B
- Free cash flow (12 months)
- $18.9B
- Cash
- $10.8B
- Debt
- $80.9B
- Diluted EPS (12 months)
- $5.81
Twelve months to September 30, 2026, from the 10-Q filed November 3, 2026.
Latest twelve months
Over the twelve months to September 30, 2026, AbbVie reported revenue of $66.0 billion, up 10.7% from a year earlier.
Its operating margin was 32.2%, up 17.0 percentage points from a year earlier: for every $100 of sales, about $32 was left as operating profit.
Net income was $10.3 billion (15.7% of revenue), 333.1% higher than a year earlier.
Operating cash flow was $20.1 billion and capital spending $1.2 billion, leaving free cash flow of $18.9 billion (28.6% of revenue).
At the end of the period it held $10.8 billion in cash and $80.9 billion in debt, a net debt position of $70.1 billion.
Five-year trend
- Revenue went from $45.8 billion in fiscal 2020 to $61.2 billion in fiscal 2025, about 6.0% a year.
- Operating margin has been steady, around 24.6%.
- Free cash flow was positive in each of the last 6 fiscal years.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| Revenue growth | 22.7% | 3.3% | -6.4% | 3.7% | 8.6% |
| Operating margin | 31.9% | 31.2% | 23.5% | 16.2% | 24.6% |
| Net income | $11.5B | $11.8B | $4.9B | $4.3B | $4.2B |
| Free cash flow | $22.0B | $24.2B | $22.1B | $17.8B | $17.8B |
| Diluted EPS | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
Fiscal years as reported in AbbVie’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 10-Q filed November 3, 2026 — quarterly report
- 8-K filed November 2, 2026 — Executive or director change
- 8-K filed October 30, 2026 — Earnings results
- 8-K filed October 15, 2026 — Executive or director change
- 8-K filed October 5, 2026 — Earnings results
- 8-K filed September 3, 2026 — Regulation FD disclosure
- 8-K filed August 18, 2026 — Other event
- 8-K filed August 5, 2026 — Other event
Companies like AbbVie
Other S&P 500 companies in Biotechnology:
- AMGNAmgenThousand Oaks, California
- BIIBBiogenCambridge, Massachusetts
- GILDGilead SciencesFoster City, California
- INCYIncyteWilmington, Delaware
- MRNAModernaCambridge, Massachusetts
- REGNRegeneron PharmaceuticalsTarrytown, New York
- VRTXVertex PharmaceuticalsBoston, Massachusetts
More from Health Care
Questions about AbbVie
Is AbbVie's revenue growing?
Yes. Revenue for the twelve months to September 30, 2026 was $66.0 billion, up 10.7% from a year earlier, according to its SEC filings.
Is AbbVie profitable?
Yes. It earned $10.3 billion in net income over the twelve months to September 30, 2026, a net margin of 15.7%.
Does AbbVie have more cash or more debt?
At September 30, 2026 it had $10.8 billion in cash and $80.9 billion in debt, so more debt than cash.
When did AbbVie last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on November 3, 2026.
Which companies are similar to AbbVie?
In the S&P 500, AbbVie is grouped in Biotechnology within the Health Care sector. Amgen (AMGN), Biogen (BIIB), Gilead Sciences (GILD), Incyte (INCY), Moderna (MRNA) are in the same group.
Understand the numbers
Source: AbbVie’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.